What is the current Price Target for the Cidara Therapeutics, Inc. stock?

The average Cidara Therapeutics, Inc. target price is $173.40. This is 66.11% higher than the current stock price. The highest price target is 101.17%, the lowest is -3.25%. 10 Analysts have issued a price target Cidara Therapeutics, Inc. 2026 .

How high will the Cidara Therapeutics, Inc. stock rise?

No reliable answer can be given as to how high the Cidara Therapeutics, Inc. stock will rise. The performance of stocks, including the Cidara Therapeutics, Inc. stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Cidara Therapeutics, Inc. stock today?

The performance of Cidara Therapeutics, Inc. stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Cidara Therapeutics, Inc. stock fall?

The decline in Cidara Therapeutics, Inc. stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Cidara Therapeutics, Inc. Forecast, price target & analysts

$104.39

5.83% yesterday

Nasdaq, Nov 07, 10:00 pm CET

ISIN

US1717571079

Symbol

CDTX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Cidara Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation

Cidara Therapeutics, Inc. Classifications & Recommendation:

Buy

93%

Hold

Cidara Therapeutics, Inc. Price Target

Target Price	$173.40
Price	$104.39
Potential	66.11% register free of charge
Number of Estimates	10

	10 Analysts have issued a price target Cidara Therapeutics, Inc. 2026 . The average Cidara Therapeutics, Inc. target price is $173.40. This is 66.11% register free of charge higher than the current stock price. The highest price target is $210.00 101.17% register free of charge , the lowest is $101.00 3.25% register free of charge .
	A rating was issued by 15 analysts: 14 Analysts recommend Cidara Therapeutics, Inc. to buy, 1 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Cidara Therapeutics, Inc. stock has an average upside potential 2026 of 66.11% register free of charge . Most analysts recommend the Cidara Therapeutics, Inc. stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '24	2025 Estimates
Earnings Per Share $	-26.74	-6.13
	409.33%	77.08%
P/E		negative

11 Analysts have issued a Cidara Therapeutics, Inc. forecast for earnings per share. The average Cidara Therapeutics, Inc. EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$-26.74	409.33%
2025	$-6.13 77.08% Unlock
2026	$-7.96 29.85% Unlock
2027	$-7.58 4.77% Unlock
2028	$-2.45 67.68% Unlock
2029	$2.03 182.86% Unlock
2030	$8.73 330.05% Unlock
2031	$18.53 112.26% Unlock
2032	$24.60 32.76% Unlock

Current	-13.06	1,781.47%
2025	-16.08 23.08% Unlock
2026	-12.40 22.89% Unlock
2027	-13.02 5.00% Unlock
2028	-40.21 208.83% Unlock
2029	48.47 220.54% Unlock
2030	11.30 76.69% Unlock
2031	5.32 52.92% Unlock
2032	4.01 24.62% Unlock

Cidara Therapeutics, Inc....

Current Cidara Therapeutics, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
HC Wainwright & Co.	Locked ➜ Locked	Locked	Oct 21 2025
Morgan Stanley	Locked ➜ Locked	Locked	Oct 16 2025
JP Morgan	Locked ➜ Locked	Locked	Oct 10 2025
WBB Securities	Locked ➜ Locked	Locked	Oct 09 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Oct 09 2025
JMP Securities	Locked ➜ Locked	Locked	Oct 03 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Sep 26 2025

Analyst Rating	Date
Locked HC Wainwright & Co.: Locked ➜ Locked	Oct 21 2025
Locked Morgan Stanley: Locked ➜ Locked	Oct 16 2025
Locked JP Morgan: Locked ➜ Locked	Oct 10 2025
Locked WBB Securities: Locked ➜ Locked	Oct 09 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Oct 09 2025
Locked JMP Securities: Locked ➜ Locked	Oct 03 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Sep 26 2025

Discover more stocks with a high price target

Novo Nordisk 60.25%

TUI 59.01%

Adidas 53.11%

Deutsche Telekom 45.39%

Meta Platforms (Facebook) 43.56%

Adyen 39.97%

BYD 38.89%

BioNTech SE - ADR 34.99%

Coinbase Global, Inc. 33.30%

Infineon 30.91%

Microsoft 29.34%

Netflix 28.46%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now